The alleged sale of Tapentadol 100 mg tablets without prescriptions at a medical store in Betalbatim raises a disturbing question about the regulation of medicines in Goa. If the allegations brought to light by a recent investigation are substantiated, this is not merely a case of one shop allegedly violating the rules. It could point to a larger failure in the monitoring of medicines that carry a risk of misuse.
The incident began when a reporter noticed a man behaving suspiciously near the railway tracks in Betalbatim. The subsequent investigation allegedly led the team to a medical store, where the shop owner was questioned about the source of the tablet. According to the reporter’s account, the owner initially denied the allegation but later allegedly acknowledged selling the medicine for around Rs 500. He refused to speak on camera, and the shop was subsequently closed.
These are serious allegations that require an impartial investigation. The claims must be independently verified, and the medical store owner must be given an opportunity to respond. However, the circumstances described are sufficient to demand answers from the authorities responsible for regulating pharmaceutical sales.
Tapentadol is a prescription opioid painkiller used to treat certain types of moderate to severe pain. It acts on the central nervous system and can cause dependence, misuse and potentially life threatening respiratory depression, particularly when taken inappropriately or combined with other substances. It is not an ordinary tablet that should be sold casually without medical supervision.
The danger lies in the possibility that medicines intended for legitimate medical treatment may find their way into the hands of people seeking their intoxicating effects. When this happens, the consequences extend beyond individual users. Families suffer, public spaces become vulnerable to substance abuse, and law enforcement agencies are left dealing with problems that could have been prevented through effective regulation.
A prescription cannot be treated as a formality.
Medicines with the potential for dependence are subject to specific regulatory requirements. Pharmacies have a responsibility to verify prescriptions, maintain appropriate records and comply with the conditions governing the sale of scheduled medicines. Drug control authorities, meanwhile, must ensure that these requirements are followed in practice and not merely on paper.
If a pharmacy is selling prescription medication without the required authorisation or documentation, the authorities must establish how frequently this has happened, who purchased the medicines and whether the supply chain has other links. An isolated transaction and a sustained pattern of unauthorised sales require different levels of investigation. Neither should be ignored.
The report also raises allegations that the activity may have continued for several years and that the shop had regular customers, including people from outside Goa. These claims should not be accepted as established facts without corroboration. Nor should the mention of people from the Northeast become an excuse to stigmatise any community. The issue is the alleged supply of potentially misused medication, not the identity or geographical origin of customers.
What matters is whether medicines were sold in violation of the law and whether any organised network was involved.
The Goa Directorate of Food and Drugs Administration must take the lead in examining the allegations. The relevant records, prescriptions, purchase invoices and stock registers should be scrutinised. If violations are established, action must follow in accordance with the law. Where evidence points to a wider drug distribution network, the police and other appropriate agencies must investigate the connections.
There is also a larger question about enforcement. Inspections cannot be limited to routine visits or checks conducted after a controversy becomes public. Authorities need risk based inspections, proper verification of pharmaceutical records and effective coordination between drug inspectors and the police. Complaints from citizens and credible media investigations should trigger timely verification rather than disappear into official files.
At the same time, the response must go beyond raids and suspensions. People who misuse prescription medicines may need medical treatment, counselling and rehabilitation. Preventing access to medicines through illegal channels and helping people overcome dependence must go hand in hand.
Goa has spent considerable time debating its drug problem, particularly its impact on tourism, public safety and young people. Yet the focus often falls on street level users and visible drug consumption. The alleged misuse of prescription medicines demands equal attention because the supply may originate from places that are expected to provide legitimate healthcare.
A medical store is entrusted with public health. That trust cannot be compromised by the pursuit of profit. If the allegations in Betalbatim are proved, the consequences must be serious enough to deter similar violations elsewhere.
The authorities must establish the facts, identify any illegal supply chain and explain what safeguards are in place to prevent a recurrence. The investigation must be transparent, evidence based and free from selective enforcement.
The central question is simple: if prescription medicines are allegedly reaching people who misuse them, where is the regulatory system failing?
Betalbatim must not become another case that attracts attention for a few days before fading from public memory. The allegations deserve a thorough investigation, and the findings must lead to corrective action. Public health cannot depend on a reporter discovering what the regulatory machinery may have failed to detect.
